Home
FULC
FULC News

Latest Fulcrum Therapeutics Inc. (FULC) News on November 25, 2024

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)

Simply Wall St.

10 days ago

Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)

Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...

GuruFocus.com

11 days ago

Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

GlobeNewswire

12 days ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

GlobeNewswire

12 days ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

GlobeNewswire

19 days ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?

Zacks

a month ago

Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Simply Wall St.

a month ago

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

Investor's Business Daily

a month ago

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...

GuruFocus.com

2 months ago

Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

Zacks

2 months ago

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

GuruFocus.com

2 months ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround

Zacks

2 months ago

Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround

MT Newswires

2 months ago

Fulcrum Therapeutics to Cut Jobs, Reprioritize R&D Activities

GuruFocus.com

2 months ago

RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares

Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

2 months ago

Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

Zacks

2 months ago

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

MT Newswires

2 months ago

RBC Downgrades Fulcrum Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $15; Speculative Risk Kept

MT Newswires

2 months ago

Top Midday Decliners

Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

Benzinga

2 months ago

Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

MT Newswires

2 months ago

Piper Sandler Cuts Price Target on Fulcrum Therapeutics to $6 From $16, Maintains Overweight Rating; Shares Plunge

MT Newswires

2 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT Newswires

2 months ago

Sector Update: Health Care

MT Newswires

2 months ago

Cantor Fitzgerald Downgrades Fulcrum Therapeutics to Neutral From Overweight

Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test

BioPharma Dive

2 months ago

Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test

MT Newswires

2 months ago

Fulcrum Therapeutics Shares Crash Premarket as Clinical Trial of Losmapimod Fails to Meet Primary Endpoint

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

GlobeNewswire

2 months ago

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

Zacks

2 months ago

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

Zacks

2 months ago

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

Benzinga

2 months ago

Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

MT Newswires

3 months ago

BofA Securities Upgrades Fulcrum Therapeutics to Neutral From Underperform, Raises Price Target to $10 From $5

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

Zacks

3 months ago

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

MT Newswires

3 months ago

RBC Adjusts Price Target on Fulcrum Therapeutics to $15 From $14, Maintains Outperform, Speculative Risk Rating

JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab

Zacks

3 months ago

JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

Zacks

3 months ago

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

Zacks

3 months ago

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

Zacks

3 months ago

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

One Fulcrum Therapeutics Insider Raised Their Stake In The Previous Year

Simply Wall St.

3 months ago

One Fulcrum Therapeutics Insider Raised Their Stake In The Previous Year

Addex Stock Soars on Crucial Update From Indivior Research Deal

Zacks

3 months ago

Addex Stock Soars on Crucial Update From Indivior Research Deal

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

Zacks

3 months ago

Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review

Fulcrum Therapeutics to Participate in Upcoming September Conferences

GlobeNewswire

3 months ago

Fulcrum Therapeutics to Participate in Upcoming September Conferences

Insmed Stock Surges 168% in the Past Six Months: Here's Why

Zacks

3 months ago

Insmed Stock Surges 168% in the Past Six Months: Here's Why

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

Zacks

3 months ago

Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids

The Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay

Zacks

3 months ago

The Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay

5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts

Zacks

3 months ago

5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

Zacks

3 months ago

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Zacks

3 months ago

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Zacks

3 months ago

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

Zacks

3 months ago

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

Zacks

3 months ago

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade

Zacks

3 months ago

Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

Zacks

3 months ago

Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

Zacks

3 months ago

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

MT Newswires

3 months ago

Fulcrum Therapeutics Names Isabel Kalofonos as Chief Commercial Officer, Heather Faulds as Chief Regulatory Affairs Officer

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

GlobeNewswire

3 months ago

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

Zacks

3 months ago

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

Zacks

3 months ago

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Zacks

3 months ago

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Zacks

4 months ago

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

Zacks

4 months ago

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Zacks

4 months ago

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Zacks

4 months ago

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know

Zacks

4 months ago

Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know

Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know

Zacks

4 months ago

Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know

Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect?

Zacks

4 months ago

Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect?

Fulcrum Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Fulcrum Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

GlobeNewswire

4 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

GlobeNewswire

4 months ago

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

Fulcrum Therapeutics (NASDAQ:FULC) delivers shareholders stellar 110% return over 1 year, surging 27% in the last week alone

Simply Wall St.

4 months ago

Fulcrum Therapeutics (NASDAQ:FULC) delivers shareholders stellar 110% return over 1 year, surging 27% in the last week alone

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

GlobeNewswire

5 months ago

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

5 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

5 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

5 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

5 months ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

5 months ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

5 months ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

5 months ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

5 months ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Where Will CrowdStrike Stock Be in 1 Year?

Motley Fool

6 months ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

GuruFocus.com

6 months ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

GuruFocus.com

6 months ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

VanEck Semiconductor ETF Is Riskier Than You Think

Motley Fool

6 months ago

VanEck Semiconductor ETF Is Riskier Than You Think

South Korea on alert for more trash balloons from the North

AFP

6 months ago

South Korea on alert for more trash balloons from the North

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Motley Fool

6 months ago

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Reuters

6 months ago

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Simply Wall St.

6 months ago

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference

GlobeNewswire

6 months ago

Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference

Goldman Sachs Predicts up to 108% Rally for These 2 ‘Strong Buy’ Stocks

TipRanks

6 months ago

Goldman Sachs Predicts up to 108% Rally for These 2 ‘Strong Buy’ Stocks

MT Newswires

6 months ago

Cantor Fitzgerald Initiates Fulcrum Therapeutics at Overweight Rating With $23 Price Target

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

Zacks

6 months ago

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

Zacks

6 months ago

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?

Zacks

6 months ago

Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?

MT Newswires

6 months ago

Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating

MT Newswires

6 months ago

Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Simply Wall St.

6 months ago

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

GuruFocus.com

6 months ago

Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug

Pharmaceutical Technology

6 months ago

Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug

Share on Social Networks: